This Is MS Multiple Sclerosis Knowledge & Support Community

I'd like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study. Side effects of alemtuzumab infusions continue after I get tired, the most troublesome are unpredictable spikes of fever and headache as a sym...

Because the price of the Gilenya is still shocking [Gilenya (fingolimod) price $ 4,000 / month - 48 000 $ / year, apparently recently dropped by about 30%] I found interesting info from Polish MS forum, it is difficult to assess how valuable: Cordyceps: breeding fungus from the Himalayas http://nauk...

Class action Being in private contact with someone who considered the issue of claim collective against the President of the Chamber, and against chief doc Hamankiewicz. Chief of neurologist professor Ryglewicz at the request of Mr. relied Hamankiewicz appearing for Ministry Ms. Ewa Kopacz, under th...

By Polish:

<shortened url>

If Gilenya’s ingredient (fingolimod) costs $14 a month, why is Novartis wanting $4,000 a month for it?

http://www.msworld.org/forum/showthread ... ost1257472

New method for the treatment of multiple sclerosis (MS) through the skin, which is to stop self-harm to the immune system of nerve tissue - are testing the Polish scientists led by prof. Christopher Selmaja Medical University of Lodz. Preliminary results of a small group of patients, researchers pre...

marcinl0 There is a really hot discussion on Polish MS forums about Rici treatment&money donation: What is the tone of the discussion? Is it supportive? Sorry, but my Polish is none existent, and Google mangles things badly. There are doubts on Polish MS forums that the actual Rici bad "TU...

There is a really hot discussion on Polish MS forums about Rici treatment&money donation: http://www.biegusy.zgora.pl/modules/xforum/viewtopic.php?topic_id=485&start=40#forumpost6321 http://helpful-hand.frix.pl/tematy/41275/wrazenia-osob-po-zabiegu-wszczepiania-stentow http://www.ldn.org.pl/...

Neurologists will use oral Multiple Sclerosis drugs as first line treatment less than 30% of the time Decision Resources finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's fingoli...